India's Tamil Nadu State Attracts ₹7,500 cr Investment in EV Sector from Hinduja Group, AstraZeneca Expands Chennai Centre with ₹716 cr

Ashok Leyland plans to invest ₹7,500 crore in Tamil Nadu for EV cell and battery manufacturing, battery energy storage systems, and EV charging stations. The investment is expected to generate over 1,000 jobs and strengthen the EV ecosystem. AstraZeneca will also expand its Chennai innovation and tech centre with a ₹716 crore investment, marking its third strategic investment in the state in two years.

In a significant move to bolster Tamil Nadu's burgeoning electric vehicle (EV) and technology sectors, Ashok Leyland and AstraZeneca have announced substantial investments. Ashok Leyland plans to invest ₹7,500 crore in the state for EV cell and battery manufacturing, battery energy storage systems, and EV charging stations. This initiative is expected to generate over 1,000 jobs and further strengthen the EV ecosystem. Additionally, AstraZeneca will expand its Chennai innovation and tech centre with a ₹716 crore investment, marking its third strategic investment in the state within two years.

Ashok Leyland, a Hinduja Group company, has been actively expanding its EV portfolio. The company's latest move is part of its broader strategy to diversify into non-auto battery storage space. By partnering with Chinese battery manufacturer CALB, which is the world’s seventh-largest supplier to the EV industry, Ashok Leyland aims to enhance its own EV portfolio and explore new market opportunities [1].

The proposed ₹7,500 crore investment by Ashok Leyland will be spread over a period of 7 to 10 years. Shenu Agarwal, Managing Director and CEO of Ashok Leyland, stated that the initial phase of production will focus on the automotive sector, gradually expanding to the non-automotive sector. A Global Centre of Excellence will be established to foster innovation in battery materials, recycling, battery management systems, and advanced manufacturing processes [1].

AstraZeneca, on the other hand, is further cementing its presence in Tamil Nadu. The company's expansion of its Chennai innovation and tech centre will contribute to the state's growing tech ecosystem. This investment, amounting to ₹716 crore, will be the third strategic move by AstraZeneca in the region over the past two years. The company's focus on innovation and technology is evident through its recent acquisitions and investments, including the completion of a $220 million sale of its China unit to AstraZeneca [2].

These investments underscore the growing importance of Tamil Nadu as a hub for EV manufacturing and technological advancements. Both Ashok Leyland and AstraZeneca are leveraging the state's strategic location and supportive business environment to drive growth and innovation.

References:
[1] https://www.financialexpress.com/business/industry-ashok-leyland-forays-into-battery-manufacturing-with-rs-5000-crore-investmentnbsp-3963431/
[2] https://www.investing.com/equities/astrazeneca